Humans don’t “own” their own genes, the cellular chemicals that define who they are and what diseases they might be at risk for.
Through more than 40,000 patents on DNA molecules, companies have essentially claimed the entire human genome for profit, report two researchers who analyzed the patents on human DNA. Their study, published March 25 in the journal Genome Medicine, raises an alarm about the loss of individual “genomic liberty.”
In their new analysis, the research team examined two types of patented DNA sequences: long and short fragments. They discovered that 41 percent of the human genome is covered by longer DNA patents that often cover whole genes. They also found that, because many genes share similar sequences within their genetic structure, if all of the “short sequence” patents were allowed in aggregate, they could account for 100 percent of the genome.
Furthermore, the study’s lead author, Dr. Christopher E. Mason of Weill Cornell Medical College, and the study’s co-author, Dr. Jeffrey Rosenfeld, an assistant professor of medicine at the University of Medicine & Dentistry of New Jersey and a member of the High Performance and Research Computing Group, found that short sequences from patents also cover virtually the entire genome — even outside of genes.
“If these patents are enforced, our genomic liberty is lost,” says Dr. Mason, an assistant professor of physiology and biophysics and computational genomics in computational biomedicine at the Institute for Computational Biomedicine at Weill Cornell. “Just as we enter the era of personalized medicine, we are ironically living in the most restrictive age of genomics. You have to ask, how is it possible that my doctor cannot look at my DNA without being concerned about patent infringement?”
The U.S. Supreme Court will review genomic patent rights in an upcoming hearing on April 15. At issue is the right of a molecular diagnostic company to claim patents not only on two key breast and ovarian cancer genes — BRCA1 and BRCA2 — but also on any small sequence of code within BRCA1, including a striking patent for only 15 nucleotides.
In its study, the research team matched small sequences within BRCA1 to other genes and found that just this one molecular diagnostic company’s patents also covered at least 689 other human genes — most of which have nothing to do with breast or ovarian cancer; rather, its patents cover 19 other cancers as well as genes involved in brain development and heart functioning.
“This means if the Supreme Court upholds the current scope of the patents, no physician or researcher can study the DNA of these genes from their patients, and no diagnostic test or drug can be developed based on any of these genes without infringing a patent,” says Dr. Mason.
ONE PATENTED SEQUENCE MATCHED MORE THAN 91 PERCENT OF HUMAN GENES
Dr. Mason undertook the study because he realized that his research into brain and cancer disorders inevitably involved studying genes that were protected by patents.
Under U.S. patent law, genes can be patented by those researchers, either at companies or institutions, who are first to find a gene that promises a useful application, such as for a diagnostic test. For example, the patents received by a company in the 1990s on BRCA1 and BRCA2 enables it to offer a diagnostic test to women who may have, or may be at risk for, breast or ovarian cancer due to mutations in one or both of these genes. Women and their doctors have no choice but to use the services of the patents’ owner, which costs $3,000 per test, “whereas any of the hundreds of clinical laboratories around the country could perform such a test for possibly much less,” says Dr. Mason.
The impact on these patents is equally onerous on research, Dr. Mason adds.
“Almost every day, I come across a gene that is patented — a situation that is common for every geneticist in every lab,” says Dr. Mason.
Dr. Mason and his research partner sought to determine how many other genes may be impacted by gene patents, as well as the overall landscape of intellectual property on the human genome.
To conduct the study, Dr. Mason and Dr. Rosenfeld examined the structure of the human genome in the context of two types of patented sequences: short and long fragments of DNA. They used matches to known genes that were confirmed to be present in patent claims, ranging from as few as 15 nucleotides (the building blocks of DNA) to the full length of all patented DNA fragments.
Before examining the patented sequences, the researchers first calculated how many genes had common segments of 15 nucleotide (15mer), and found that every gene in the human genome matched at least one other gene in this respect, ranging from as few as five matches 15mer to as many as 7,688 gene matches. They also discovered that 99.999 percent of 15mers in the human genome are repeated at least twice.
“This demonstrates that short patent sequences are extremely non-specific and that a 15mer claim from one gene will always cross-match and patent a portion of another gene as well,” says Dr. Mason. “This means it is actually impossible to have a 15mer patent for just one gene.”
Next, researchers examined the total sequence space in human genes covered by 15mers in current patent claims. They found 58 patents whose claims covered at least 10 percent of all bases of all human genes. The broadest patent claimed sequences that matched 91.5 percent of human genes. Then, when they took existing gene patents and matched patented 15mers to known genes, they discovered that 100 percent of known genes are patented.
“There is a real controversy regarding gene ownership due to the overlap of many competing patent claims. It is unclear who really owns the rights to any gene,” says Dr. Rosenfeld. “While the Supreme Court is hearing one case concerning just the BRCA1 patent, there are also many other patents whose claims would cover those same genes. Do we need to go through every gene to look at who made the first claim to that gene, even if only one small part? If we resort to this rule, then the first patents to be granted for any DNA will have a vast claim over portions of the human genome.”
A further issue of concern is that patents on DNA can readily cross species boundaries. A company can have a patent that they received for cow breeding and have that patent cover a large percentage of human genes. Indeed, the researchers found that one company owns the rights to 84 percent of all human genes for a patent they received for cow breeding. “It seems silly that a patent designed to study cow genetics also claims the majority of human genes,” says Dr. Rosenfeld.
Finally, they also examined the impact of longer claimed DNA sequences from existing gene patents, which ranged from a few dozen bases up to thousands of bases of DNA, and found that these long, claimed sequences matched 41 percent (9,361) of human genes. Their analysis concluded that almost all clinically relevant genes have already been patented, especially for short sequence patents, showing all human genes are patented many times over.
“This is, so to speak, patently ridiculous,” adds Dr. Mason. “If patent claims that use these small DNA sequences are upheld, it could potentially create a situation where a piece of every gene in the human genome is patented by a phalanx of competing patents.”
The Latest Bing News on:
Humans don’t “own” their own genes
- Us Versus Them: An Intractable Problem in Human Nature?on April 26, 2024 at 6:01 pm
"Us versus them" is one of the most poisonous, yet enduring, dynamics in human history. People divide themselves into groups quite easily in response to physical and behavioral differences. We need to ...
- Genomic analysis of a species of zooplankton questions assumptions about speciation and gene regulationon April 26, 2024 at 6:40 am
When two animals look the same, eat the same, behave the same way, and live in similar environments, one might expect that they belong to the same species.
- Mom Explains Concept of 'Coming Out' to Gen Alpha Kids, They Don't Get Iton April 25, 2024 at 8:38 am
"Kids are generally tolerant by nature," Emmaline Carroll Southwell told Newsweek, but that didn't prepare her for her children's adorable passion.
- Dining across the divide: ‘She felt our generation shouldn’t be held responsible for the massive imbalance between us and young people’on April 25, 2024 at 3:30 am
Could they agree on immigration and housing? And why did the conversation turn to pigeon racing?
- Why do some people have a will but others don’t?on April 24, 2024 at 4:07 am
Without a will, assets can get dispersed among multiple heirs, which can be a particular problem for people whose major asset is their home. Despite the advantages of having a will, only about ...
- What you eat could alter your unborn children and grandchildren’s genes and health outcomeson April 23, 2024 at 5:36 am
Studies show a parent’s poor diet could affect the genes of generations to come – and set up children and grandchildren for obesity and cardiovascular issues.
- Why Don’t We Have A Cure For Cavities? Inside the Decades-Long Scientific Queston April 23, 2024 at 4:00 am
Scientists have been trying to manipulate the way our oral microbes interact with our teeth to prevent cavities for decades — they might be closer than ever.
- Squatter crisis could force homeowners to take matters into their own hands if cops keep being reluctant: experton April 21, 2024 at 8:25 am
Shawn Meaike told The Post that he's scared angry homeowners will take things into their own hands if the cops don't start booting out ... that you push people too far,” Meaike said.
- National Politicson April 13, 2024 at 5:19 am
“Our media consultant did say, ‘Marilyn, you don’t have to do this, the issue is compelling enough on its own ... “I think a lot of people wish they could tell their story, but ...
- Progressive Candidates Are Increasingly Sharing Their Own Abortion Stories After Roe's Demiseon April 13, 2024 at 3:48 am
Progressive Candidates Are Increasingly Sharing Their Own Abortion Stories ... “I think a lot of people wish they could tell their story, but either they don’t have the platform or they ...
The Latest Google Headlines on:
Humans don’t “own” their own genes
[google_news title=”” keyword=”Humans don’t own their own genes” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
[/vc_column_text]
The Latest Bing News on:
Patents on human DNA
- Precision Biosciences gets grant for engineered meganucleases for modifying human mitochondrial dnaon April 24, 2024 at 6:15 am
Unlock the potential of gene therapy with Precision Biosciences' patented MTEM technology for editing human mitochondrial DNA. Learn more about this groundbreaking innovation now!
- FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirementson April 23, 2024 at 3:22 pm
"Due to significant changes and essential restructuring undertaken in 2023, which has continued in 2024, there has been a delay in filing our Form 10-K," explained Mark White, Interim CEO of Foxo ...
- Unilever wants you to wash the stains that are mostly invisibleon April 21, 2024 at 9:50 pm
Unilever's innovations like Persil Wonder Wash, endorsed by Usain Bolt, aim for quick rinsing. CEO Hein Schumacher targets growth as Eduardo Campanella introduces pungent variants. Keith Rutherford ...
- Researchers discover urine-based test to detect head and neck canceron April 16, 2024 at 12:03 pm
Researchers from the University of Michigan Health Rogel Cancer Center have created a urine-based test that detects pieces of DNA fragments released by head and neck tumors. The test could potentially ...
- Which ASX companies are resurrecting abandoned drugs? Part 1on April 15, 2024 at 12:30 pm
Race Oncology (ASX:RAC) is among ASX-listed biotechs resurrecting or repurposing abandoned or underutilised drugs.
- USPTO warns patent lawyers not to pass off AI inventions as humanon April 10, 2024 at 10:54 am
The USPTO said in separate guidance in February that it will only grant patents for AI-assisted inventions that feature "significant" human contributions. The office elaborated on Wednesday ...
- 4basebio files for patent on novel DNA typeon April 10, 2024 at 4:55 am
(Sharecast News) - 4basebio confirmed the provision of its synthetic DNA to an unnamed tier-one pharmaceutical company on Wednesday. 4basebio PLC - Cambridge, England-based life sciences company ...
- Cloaking Device: Liu, Joung Launch $100M Nvelop Therapeutics to Advance Delivery of Genetic Cargoon April 9, 2024 at 8:00 am
A $100-million startup is developing not one but two answers to the challenge that has long dogged the gene therapy field: How can genetic medicines best be delivered to patients safely and ...
- A nail in the coffin for DNA sequence patents?on January 10, 2024 at 8:32 am
3, which describes human cell surface antigen p38 and a monoclonal antibody that binds the antigen. The patent provides a theoretical ... methods of isolating a DNA molecule say nothing about ...
- China’s quest for human genetic data spurs fears of a DNA arms raceon September 21, 2023 at 2:09 pm
BGI acquired the patents to the American firm’s DNA-sequencing machines and soon ... to specialize in deciphering the whole genomes of human subjects. The equipment would be Chinese, officials ...
The Latest Google Headlines on:
Patents on human DNA
[google_news title=”” keyword=”patents on human DNA” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]